A growth modulation index-based geistra score as a new prognostic tool for trabectedin efficacy in patients with advanced soft tissue sarcomas

The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with...

Descripción completa

Detalles Bibliográficos
Autores: Martínez Trufero, Javier|||0000-0002-0997-2573, Sande-González, Luis Miguel de, Luna, Pablo, Martín-Broto, Javier|||0000-0001-7350-6916, Alvarez, Rosa|||0000-0003-0935-8298, Marquina, Gloria|||0000-0002-8961-9787, Diaz-Beveridge, Roberto|||0000-0003-3719-7014, Poveda, Andrés, Cano, Juana María|||0000-0002-2493-0988, Cruz-Jurado, Josefina|||0000-0001-6398-1641, López Pousa, Antonio, Salgado, María Angeles Vaz, Valverde Morales, Claudia Maria, Sevilla, Isabel, Martínez-García, Jerónimo|||0000-0002-2295-5161, Rubio-Casadevall, Jordi|||0000-0002-3516-6970, de Juan Ferre, Ana|||0000-0002-5852-9068, Carrasco, Juan Antonio, Moura, David S., Gurruchaga-Sotes, Ibon|||0000-0003-2519-8079, Gutiérrez, Antonio|||0000-0001-9062-077X
Tipo de recurso: artículo
Fecha de publicación:2021
País:España
Institución:Universitat Autònoma de Barcelona
Repositorio:Dipòsit Digital de Documents de la UAB
Idioma:inglés
OAI Identifier:oai:ddd.uab.cat:272118
Acceso en línea:https://ddd.uab.cat/record/272118
https://dx.doi.org/urn:doi:10.3390/cancers13040792
Access Level:acceso abierto
Palabra clave:Trabectedin
Sarcoma
Growth modulation index
Prognostic score
L-sarcoma
GEISTRA
Descripción
Sumario:The aim of this study was to identify an easily reliable prognostic score that selects the subset of advanced soft tissue sarcoma (ASTS) patients with a higher benefit with trabectedin in terms of time to progression and overall survival. A retrospective series of 357 patients with ASTS treated with trabectedin as second-or further-line in 19 centers across Spain was analyzed. First, it was confirmed that patients with high growth modulation index (GMI.

Similares en LA Referencia